Free tool
FAERS Monitor: Midazolam Hydrochloride (Autoinjector)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216359 or its brand name (Midazolam Hydrochloride (Autoinjector), Midazolam Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,487
Serious
1,393
94% of reports
Hospitalization
805
Death reported
391
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death346
- therapy interrupted158
- therapy cessation113
- hospitalisation95
- surgery72
- condition aggravated53
- pneumonia44
- fall36
- cerebrovascular accident31
- covid-1931
- infection25
- pain25
- fatigue21
- intentional dose omission18
- dyspnoea17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 4 |
| 2018 | 41 |
| 2019 | 400 |
| 2020 | 562 |
| 2021 | 420 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 4 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 158 | 31.3 | 27.0 | 4,616 |
| therapy cessationSignal | 113 | 31.2 | 26.1 | 3,274 |
| surgerySignal | 72 | 17.4 | 13.9 | 1,098 |
| intentional dose omissionSignal | 18 | 8.9 | 5.6 | 119 |
| hospitalisationSignal | 95 | 8.8 | 7.2 | 649 |
| deathSignal | 346 | 5.7 | 5.2 | 1,387 |
| cerebrovascular accidentSignal | 31 | 2.6 | 1.8 | 29 |
| covid-19Signal | 31 | 2.5 | 1.8 | 27 |
| condition aggravatedSignal | 53 | 2.5 | 1.9 | 45 |
| infectionSignal | 25 | 2.4 | 1.7 | 20 |
| pneumonia | 44 | 1.9 | 1.4 | 19 |
| fall | 36 | 1.5 | 1.1 | 6 |
| pain | 25 | 0.6 | 0.4 | 8 |
| dyspnoea | 17 | 0.4 | 0.3 | 13 |
| fatigue | 21 | 0.4 | 0.2 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.